Despite the promising roles of GPR3 (Huang et al., 2015; Capaldi et al., 2018), GPR6, and GPR12 in neurodegenerative diseases, including AD, further research is required to fully elucidate their mechanisms of action and validate them as viable therapeutic targets. This evidence concerns the gene GPR6 and neurodegenerative disease.